IPM Take
Precision cardiology likes to talk about genes, biomarkers and algorithms. But the exposome may be just as personal, and far less voluntary.
People can be advised to stop smoking, improve their diet or take medication. They cannot individually opt out of polluted air, degraded plastics, unsafe workplaces or contaminated environments.
This study is too small to declare microplastics a proven cause of heart attacks. It is large enough to challenge the political fiction that cardiovascular risk is created only by individual choices. If plastic particles are entering the coronary circulation, prevention policy may eventually need to regulate the environment around the patient, not just the behaviour of the patient.
Executive Summary
A cross-sectional study published in the European Heart Journal examined micro- and nanoplastics in coronary and peripheral blood from 61 patients undergoing coronary angiography in Italy. Participants included 19 patients with ST-segment elevation myocardial infarction, 20 with chronic coronary syndromes and 22 with normal coronary arteries.
Micro- and nanoplastics were detected in 84.2% of patients experiencing a serious heart attack, compared with 40% of patients with chronic coronary disease and 31.8% of controls. Polyethylene was the predominant polymer, accounting for 97% of detected polymers. Heart attack patients also had greater polymer diversity and higher concentrations in coronary blood.
Plastic detection co-occurred with higher inflammatory markers, smoking and greater exposure to fine particulate air pollution. Smoking history was the only independent predictor retained in the multivariable analysis, with smokers having approximately 5.7 times the odds of detectable micro- and nanoplastics.
The findings do not establish that plastic particles cause myocardial infarction. The study was small, observational and cross-sectional, meaning it cannot determine whether exposure preceded the cardiac event or whether other factors explain the association. Nevertheless, it adds to earlier evidence identifying micro- and nanoplastics in human atherosclerotic plaques and associating their presence with subsequent cardiovascular events.
The research therefore represents a Signal, not a clinical Alert. It should trigger larger studies, better exposure measurement and stronger consideration of environmental risk in cardiovascular prevention, not routine microplastic blood testing or premature treatment claims.
Why it matters
- Policymakers and public authorities: Cardiovascular prevention strategies may need to address air quality, tobacco exposure and plastic pollution alongside conventional risk factors.
- Clinicians and hospitals: Environmental exposure is becoming part of the cardiovascular risk conversation, but the evidence is not mature enough to guide routine testing or individual treatment decisions.
- Regulators: Existing microplastic policies largely target intentionally added particles and specific industrial losses. Diffuse exposure from degraded plastics, air pollution and consumer environments remains harder to regulate.
- Researchers and academia: Larger prospective studies must establish temporality, dose-response relationships, standardised measurement methods and whether reducing exposure lowers cardiovascular risk.
- Patients and advocates: The findings should not be used to frighten patients or shift responsibility onto individuals. Many environmental exposures cannot be controlled through personal behaviour alone.
When a patient arrives with a heart attack, cardiology searches for familiar culprits.
A ruptured plaque. High cholesterol. Smoking. Diabetes. Hypertension. Genetics.
Researchers in Italy have now reported finding something else in the blood flowing through the arteries that supply the heart: plastic.
The study, published in the European Heart Journal on 14 July 2026, examined 61 patients undergoing coronary angiography at hospitals in Rome and Verona. Researchers collected blood directly from the coronary circulation and from peripheral blood, then analysed the samples for micro- and nanoplastics using two specialised laboratory techniques.
The patients were divided into three groups: 19 experiencing an ST-segment elevation myocardial infarction, 20 with chronic coronary syndromes and 22 whose coronary arteries appeared normal.
The differences were striking.
Micro- and nanoplastics were detected in 84.2% of the heart attack group. Detection fell to 40% among patients with chronic coronary disease and 31.8% among controls. Patients experiencing heart attacks also had higher concentrations and a wider variety of polymers. Polyethylene, widely used in packaging and consumer products, was the predominant polymer detected.
That finding is disturbing.
It is not proof.
The researchers did not follow healthy people over time to determine whether higher plastic exposure predicted future heart attacks. They examined patients at the point of coronary investigation. The study therefore cannot establish whether microplastics contributed to the cardiac event, whether the event affected particle distribution, or whether both reflected other exposures and risk factors.
The sample was also small. Only 19 patients were in the heart attack group. With numbers this limited, a dramatic percentage difference can still be vulnerable to confounding and statistical instability.
The most responsible interpretation is therefore neither dismissal nor panic.
It is attention.
The study becomes more provocative when smoking and air pollution are added to the picture. Patients exposed to higher long-term levels of PM2.5 were more likely to have detectable plastics. Every patient who both smoked and experienced higher air-pollution exposure had detectable micro- and nanoplastics, compared with 12.5% of patients with neither exposure.
After adjustment, however, smoking history was the only independent predictor of detectable particles. Smokers had approximately 5.7 times the odds of detection, although the confidence interval was wide, reflecting the small study population.
This distinction matters.
Headlines may imply that the research proves polluted air pumps plastic directly into the heart and triggers myocardial infarction. The data do not go that far. They identify a relationship between environmental exposures, detectable plastic particles, inflammation and coronary disease severity.
The inflammatory findings add biological plausibility. Patients with heart attacks had higher concentrations of interleukin-6 and tumour necrosis factor-alpha, two markers associated with inflammatory processes. The accompanying editorial argues that experimental evidence links micro- and nanoplastics with oxidative stress, endothelial dysfunction and inflammation, mechanisms that could theoretically contribute to vascular injury.
But plausible biology is not the same as proven clinical causation.
This is where health policy must resist two familiar failures.
The first is waiting for absolute certainty before taking environmental risk seriously.
The second is turning preliminary science into an individualised health market before the evidence is ready.
A commercial blood test claiming to measure personal microplastic cardiovascular risk would move far ahead of this study. There is no validated threshold distinguishing a safe concentration from a dangerous one, no established clinical pathway for interpreting the result and no proven intervention showing that lowering an individual’s measured burden prevents heart attacks.
Patients do not need another expensive test that generates fear without a treatment pathway.
Policymakers, however, already have reasons to reduce exposure.
The European Union has set a target of cutting microplastic releases by 30% by 2030. It has introduced restrictions on intentionally added microplastics and adopted rules requiring companies handling plastic pellets to prevent, contain and report losses.
Those measures are important, but they expose the limits of current governance.
Microplastics are not released only because manufacturers intentionally add them to products or spill industrial pellets. They also emerge as tyres, textiles, packaging, paints and larger plastic waste degrade. These diffuse sources cross traditional regulatory boundaries involving transport, waste, chemicals, air quality, consumer products and industrial policy.
Cardiovascular policy has historically treated these areas as external to its mandate.
That separation is becoming harder to defend.
In 2024, a study published in the New England Journal of Medicine detected micro- and nanoplastics in carotid artery plaques. Patients whose plaques contained the particles experienced a higher rate of myocardial infarction, stroke or death during follow-up than those without detectable particles. That study was also observational and could not establish causality, but it placed plastics inside vascular tissue and linked their presence with clinically important outcomes.
The new Italian study moves the signal into the coronary circulation itself.
Together, the studies suggest a research agenda that cardiovascular medicine can no longer leave entirely to environmental scientists.
Future work must include larger and more diverse populations, prospective follow-up, rigorous contamination controls, standardised laboratory methods and detailed assessment of exposure sources. Researchers will need to determine whether particle type, size, concentration or duration of exposure matters most. Above all, studies must test whether reducing exposure changes cardiovascular outcomes.
The equity dimension must also be explicit.
Exposure to polluted air, tobacco smoke, traffic, industrial emissions and poor-quality environments is not distributed randomly. Lower-income communities and people living near major roads, industrial sites or inadequate waste infrastructure often carry a disproportionate environmental burden.
Calling these exposures “lifestyle risk factors” would be politically convenient and scientifically dishonest.
A person can make choices within an environment. They cannot choose the environment they were priced into.
This does not mean cardiologists should begin asking every patient how much plastic is in their blood. It means cardiovascular prevention must become more honest about where risk originates.
Some risk is genetic.
Some risk is behavioural.
Some risk is manufactured, sold, emitted and politically tolerated.
The first policy mistake would be declaring that microplastics have been proven to cause heart attacks.
The second would be waiting for perfect certainty while environmental exposure quietly becomes another cardiovascular inequality.
